“Hypertriglyceridemia Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertriglyceridemia Market.

The Hypertriglyceridemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hypertriglyceridemia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Hypertriglyceridemia treatment therapies with a considerable amount of success over the years.

• Hypertriglyceridemia companies working in the treatment market are Eli Lilly and Company, OrsoBio, Marea Therapeutics, Arrowhead Pharmaceuticals, NorthSea Therapeutics, Ionis Pharmaceuticals, 89bio, Inc., and others, are developing therapies for the Hypertriglyceridemia treatment

• Emerging Hypertriglyceridemia therapies in the different phases of clinical trials are- LY3875383, TLC-2716, MAR001, ARO-APOC3, NST-1024, Olezarsen, Pegozafermin, and others are expected to have a significant impact on the Hypertriglyceridemia market in the coming years.

• In May 2025, Ionis Pharmaceuticals reported positive topline results from the global Phase III Essence trial of Tryngolza (olezarsen) in individuals with moderate hypertriglyceridemia and/or at risk of atherosclerotic cardiovascular disease (ASCVD). Characterized by fasting triglyceride (TG) levels between ≥150mg/dL and <500mg/dL, the condition presents a significant cardiovascular risk. The randomized, multicenter, double-blind, placebo-controlled trial—conducted in partnership with the TIMI Study Group—evaluated the safety and efficacy of olezarsen in this target population.

• In March 2025, Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”), a clinical-stage biopharma company focused on developing novel biologics for metabolic and cancer-related diseases, has announced the completion of patient enrollment in its Phase 2 clinical trial of DR10624 for treating severe hypertriglyceridemia (SHTG). DR10624 is a first-in-class tri-specific agonist targeting FGF21R, GCGR, and GLP-1R. The randomized, double-blind, placebo-controlled study (“DR10624-201 study”) is assessing the safety and efficacy of three different dose levels of DR10624 in adults with SHTG, defined by fasting triglyceride levels ≥5.65 mmol/L (500 mg/dL). A total of 79 patients are participating in the 12-week trial.

Hypertriglyceridemia Overview

Hypertriglyceridemia is a condition characterized by high levels of triglycerides (a type of fat) in the blood. Triglycerides are produced from excess calories and are stored in fat cells. Elevated triglyceride levels can increase the risk of cardiovascular diseases, pancreatitis, and metabolic syndrome. Causes include obesity, diabetes, excessive alcohol intake, and genetic factors. It is typically managed through dietary changes, exercise, and medications.

Get a Free Sample PDF Report to know more about Hypertriglyceridemia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hypertriglyceridemia-pipeline-insight

Emerging Hypertriglyceridemia Drugs Under Different Phases of Clinical Development Include:

• LY3875383: Eli Lilly and Company

• TLC-2716: OrsoBio

• MAR001: Marea Therapeutics

• ARO-APOC3: Arrowhead Pharmaceuticals

• NST-1024: NorthSea Therapeutics

• Olezarsen: Ionis Pharmaceuticals

• Pegozafermin: 89bio, Inc.

Hypertriglyceridemia Route of Administration

Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Hypertriglyceridemia Molecule Type

Hypertriglyceridemia Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Hypertriglyceridemia Pipeline Therapeutics Assessment

• Hypertriglyceridemia Assessment by Product Type

• Hypertriglyceridemia By Stage and Product Type

• Hypertriglyceridemia Assessment by Route of Administration

• Hypertriglyceridemia By Stage and Route of Administration

• Hypertriglyceridemia Assessment by Molecule Type

• Hypertriglyceridemia by Stage and Molecule Type

DelveInsight’s Hypertriglyceridemia Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Hypertriglyceridemia product details are provided in the report. Download the Hypertriglyceridemia pipeline report to learn more about the emerging Hypertriglyceridemia therapies

Some of the key companies in the Hypertriglyceridemia Therapeutics Market include:

Key companies developing therapies for Hypertriglyceridemia are – Merck, Julphar, Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer, AbbVie, Sanofi, GlaxoSmithKline, Biocon, Novo Nordisk, Tonghua Dongbao Pharmaceutical, Oramed Pharmaceuticals, and others.

Hypertriglyceridemia Pipeline Analysis:

The Hypertriglyceridemia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hypertriglyceridemia with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertriglyceridemia Treatment.

• Hypertriglyceridemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Hypertriglyceridemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertriglyceridemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hypertriglyceridemia drugs and therapies

Hypertriglyceridemia Pipeline Market Drivers

• Increased Consumption of Unhealthy Diet, increase in research and developmental activities are some of the important factors that are fueling the Hypertriglyceridemia Market.

Hypertriglyceridemia Pipeline Market Barriers

• However, high-cost associated with the disease, limited awareness about the disease and other factors are creating obstacles in the Hypertriglyceridemia Market growth.

Scope of Hypertriglyceridemia Pipeline Drug Insight

• Coverage: Global

• Key Hypertriglyceridemia Companies: Eli Lilly and Company, OrsoBio, Marea Therapeutics, Arrowhead Pharmaceuticals, NorthSea Therapeutics, Ionis Pharmaceuticals, 89bio, Inc., and others

• Key Hypertriglyceridemia Therapies: LY3875383, TLC-2716, MAR001, ARO-APOC3, NST-1024, Olezarsen, Pegozafermin, and others

• Hypertriglyceridemia Therapeutic Assessment: Hypertriglyceridemia current marketed and Hypertriglyceridemia emerging therapies

• Hypertriglyceridemia Market Dynamics: Hypertriglyceridemia market drivers and Hypertriglyceridemia market barriers

Request for Sample PDF Report for Hypertriglyceridemia Pipeline Assessment and clinical trials

Table of Contents

1. Hypertriglyceridemia Report Introduction

2. Hypertriglyceridemia Executive Summary

3. Hypertriglyceridemia Overview

4. Hypertriglyceridemia- Analytical Perspective In-depth Commercial Assessment

5. Hypertriglyceridemia Pipeline Therapeutics

6. Hypertriglyceridemia Late Stage Products (Phase II/III)

7. Hypertriglyceridemia Mid Stage Products (Phase II)

8. Hypertriglyceridemia Early Stage Products (Phase I)

9. Hypertriglyceridemia Preclinical Stage Products

10. Hypertriglyceridemia Therapeutics Assessment

11. Hypertriglyceridemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hypertriglyceridemia Key Companies

14. Hypertriglyceridemia Key Products

15. Hypertriglyceridemia Unmet Needs

16 . Hypertriglyceridemia Market Drivers and Barriers

17. Hypertriglyceridemia Future Perspectives and Conclusion

18. Hypertriglyceridemia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/